Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 20.79% is 53% above its 5-year average of 13.58%, near the high end of its 5-year range (-3.49%–24.06%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.15% above its 12-month average of 20.56%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 20.79%.
RETURN ON EQUITY (ROE)
20.79%
RETURN ON EQUITY (ROE) AVG TTM
20.56%
RETURN ON EQUITY (ROE) AVG 3Y
18.13%
RETURN ON EQUITY (ROE) AVG 5Y
13.58%
RETURN ON EQUITY (ROE) AVG 10Y
19.10%
RETURN ON EQUITY (ROE) AVG 15Y
17.32%
RETURN ON EQUITY (ROE) AVG 20Y
23.19%
CURRENT VS TTM AVG
+1.15%
CURRENT VS 3Y AVG
+14.70%
CURRENT VS 5Y AVG
+53.15%
CURRENT VS 10Y AVG
+8.85%
CURRENT VS 15Y AVG
+20.04%
CURRENT VS 20Y AVG
-10.33%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+59.83%
vs the sector median at left
AstraZeneca PLC
Market Cap
$247.58B
Return on Equity (ROE)
20.79%
TTM Avg
20.56%
3Y Avg
18.13%
5Y Avg
13.58%
Market Cap
$224.15B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$206.42B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$195.43B
Return on Equity (ROE)
53.50%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
Market Cap
$179.79B
Return on Equity (ROE)
-27.39%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
Market Cap
$178.87B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
Market Cap
$157.59B
Return on Equity (ROE)
5.09%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$339.06B
Return on Equity (ROE)
38.06%
TTM Avg
32.06%
3Y Avg
36.93%
5Y Avg
40.66%
Market Cap
$352.61B
Return on Equity (ROE)
14.34%
TTM Avg
14.18%
3Y Avg
19.86%
5Y Avg
21.18%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $247.58B | 20.79% | 20.56% | 18.13% | 13.58% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.15B | 13.25% | 12.70% | 13.51% | 15.24% |
| Amgen Inc. (AMGN)vs › | $206.42B | 74.80% | 79.33% | 111.35% | 101.76% |
| Novo Nordisk A/S (NVO)vs › | $195.43B | 53.50% | 61.58% | 67.05% | 123.42% |
| Gilead Sciences, Inc. (GILD)vs › | $179.79B | -27.39% | 19.98% | 21.60% | 19.44% |
| Abbott Laboratories (ABT)vs › | $178.87B | 10.61% | 20.32% | 18.59% | 17.97% |
| Pfizer Inc. (PFE)vs › | $157.59B | 5.09% | 9.04% | 13.32% | 16.07% |
| Roche Holding AG (RHHBY)vs › | $339.06B | 38.06% | 32.06% | 36.93% | 40.66% |
| UnitedHealth Group Incorporated (UNH)vs › | $352.61B | 14.34% | 14.18% | 19.86% | 21.18% |
| Danaher Corporation (DHR)vs › | $141.00B | 7.61% | 7.38% | 9.51% | 10.24% |
ROE
20.8%
ROA
9.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 20.79% |
| 2026-03-31 | 21.95% |
| 2025-12-31 | 21.01% |
| 2025-09-30 | 20.48% |
| 2025-06-30 | 18.55% |
| 2025-03-30 | 18.94% |
| 2024-12-31 | 17.25% |
| 2024-09-30 | 15.95% |
| 2024-06-30 | 16.30% |
| 2024-03-31 | 16.91% |
| 2023-12-31 | 15.21% |
| 2023-09-30 | 15.85% |
| 2023-06-30 | 16.48% |
| 2023-03-31 | 13.14% |
| 2022-12-31 | 8.87% |
| 2022-09-30 | 5.80% |
| 2022-06-30 | -3.49% |
| 2022-03-31 | -2.93% |
| 2021-12-31 | 0.29% |
| 2021-09-30 | 3.70% |
| 2021-06-30 | 24.06% |
| 2021-03-31 | 27.56% |
| 2020-12-31 | 20.46% |
| 2020-09-30 | 20.48% |
| 2020-06-30 | 17.55% |
| 2020-03-31 | 14.12% |
| 2019-12-31 | 10.17% |
| 2019-09-30 | 16.90% |
| 2019-06-30 | 16.15% |
| 2019-03-31 | 22.97% |
| 2018-12-31 | 17.28% |
| 2018-09-30 | 20.29% |
| 2018-06-30 | 21.17% |
| 2018-03-31 | 21.71% |
| 2017-12-31 | 20.06% |
| 2017-09-30 | 25.81% |
| 2017-06-30 | 28.35% |
| 2017-03-31 | 26.10% |
| 2016-12-31 | 23.56% |
| 2016-09-30 | 18.86% |
| 2016-06-30 | 16.42% |
| 2016-03-31 | 19.82% |
| 2015-12-31 | 15.28% |
| 2015-09-30 | 9.78% |
| 2015-06-30 | 6.46% |
| 2015-03-31 | 7.55% |
| 2014-12-31 | 6.28% |
| 2014-09-30 | 5.04% |
| 2014-06-30 | 9.18% |
| 2014-03-31 | 9.55% |
| 2013-12-31 | 11.01% |
| 2013-09-30 | 19.79% |
| 2013-06-30 | 20.96% |
| 2013-03-31 | 25.30% |
| 2012-12-31 | 26.35% |
| 2012-09-30 | 28.22% |
| 2012-06-30 | 37.16% |
| 2012-03-31 | 40.44% |
| 2011-12-31 | 42.95% |
| 2011-09-30 | 42.28% |
| 2011-06-30 | 34.69% |
| 2011-03-31 | 36.61% |
| 2010-12-31 | 34.69% |
| 2010-09-30 | 36.09% |
| 2010-06-30 | 38.71% |
| 2010-03-31 | 39.33% |
| 2009-12-31 | 36.40% |
| 2009-09-30 | 37.21% |
| 2009-06-30 | 38.39% |
| 2009-03-31 | 43.84% |
| 2008-12-31 | 38.34% |
| 2008-09-30 | 37.99% |
| 2008-06-30 | 35.88% |
| 2008-03-31 | 37.62% |
| 2007-12-31 | 37.86% |
| 2007-09-30 | 39.42% |
| 2007-06-30 | 40.45% |
| 2007-03-31 | 44.42% |
| 2006-12-31 | 39.48% |
| 2006-09-30 | 39.73% |
| 2006-06-30 | 36.69% |
| 2006-03-31 | 33.26% |
| 2005-12-31 | 34.61% |
| 2005-09-30 | 34.31% |
| 2005-06-30 | 33.12% |
| 2005-03-31 | 29.83% |
| 2004-12-31 | 26.45% |
| 2004-09-30 | 25.32% |
| 2004-06-30 | 23.94% |
| 2004-03-31 | 23.54% |
| 2003-12-31 | 23.04% |
| 2003-09-30 | 20.89% |
| 2003-06-30 | 21.17% |
